Novo Nordisk AS is to team up with Dutch biotech Staten Biotechnology to develop novel treatments for hypertriglyceridaemia, in a deal worth €430m in milestone payments to the latter company, with a potential buyout also on the table.
Novo Nordisk will provide R&D funding and support for Staten to develop its preclinical lead asset STT-5058, a humanized, monoclonal antibody (MAb), licensed from its